Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

First-Dollar Coverage For Some Drugs Allowable With Health Savings Accounts

This article was originally published in The Pink Sheet Daily

Executive Summary

The Treasury Department says statins and ACE inhibitors would qualify for the preventive care exemption to high-deductible health plans. The exemption means that HSA holders will remain sheltered from prices of qualifying drugs.

You may also be interested in...



CMS Considering Obesity Drug Coverage Under Medicare

The agency is "open" to considering coverage of obesity drugs in light of a recent change to its obesity policy, but seeks comment on how it can legally do so, given the prohibition of weight loss drug coverage under the Medicare Modernization Act.

Endo’s Lidoderm Mailings Draw FDA Warning Letter For Unsubstantiated Claims

FDA asks Endo to disseminate “corrective messages” to doctors who received the violative promotional materials, which the agency says omit risk information and contain unsubstantiated effectiveness claims.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060114

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel